Optimum Medical

optimummedical.co.uk

Optimum Medical are a UK based healthcare manufacturer, specialising in healthcare lubricant gel and urology products. You'll find our products in more than 60 countries around the world - as well as every single NHS hospital in the UK. Our products aim to influence, support and improve the quality of healthcare around the world. We listen to our customer’s needs and respond by continually developing new products and evolving our existing ranges. Our products are designed to ensure patient outcomes and patient care is the best it can possibly be.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

news image

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More

INDUSTRIAL IMPACT

AGILENT AND A*STAR’S SIFBI SIGN RESEARCH COLLABORATION AGREEMENT TO ADVANCE SINGAPORE AGRI-FOOD INDUSTRY

Agilent Technologies Inc. | January 27, 2022

news image

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive innovation in food, nutrition, ingredients, industrial b...

Read More

INDUSTRIAL IMPACT

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

news image

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More

INDUSTRIAL IMPACT

ENVISAGENICS ANNOUNCES RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB

Envisagenics | December 05, 2022

news image

Envisagenics, an Artificial Intelligence driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based ...

Read More
news image

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More
news image

INDUSTRIAL IMPACT

AGILENT AND A*STAR’S SIFBI SIGN RESEARCH COLLABORATION AGREEMENT TO ADVANCE SINGAPORE AGRI-FOOD INDUSTRY

Agilent Technologies Inc. | January 27, 2022

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive innovation in food, nutrition, ingredients, industrial b...

Read More
news image

INDUSTRIAL IMPACT

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More
news image

INDUSTRIAL IMPACT

ENVISAGENICS ANNOUNCES RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB

Envisagenics | December 05, 2022

Envisagenics, an Artificial Intelligence driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based ...

Read More